Generation Bio saw the highest growth of 3.49% in patent filings in June and no patents were granted in April in Q2 2024. Compared to Q1 2024, Q2 2024 saw an increase in patent filings by 0.36% and no change in grants. GlobalData’s DataBook provides a comprehensive analysis of Generation Bio‘s patent filings and grants. Buy the databook here.
Generation Bio has been focused on protecting inventions in World Intellectual Property Organization(WIPO) with six publications in Q2 2024
The World Intellectual Property Organization(WIPO) Patent Office dominates the patent filings with nearly 50% of filings. The World Intellectual Property Organization(WIPO), European Patent Office(EPO), Israel(IL), and South Korea(KR) patent Office are among the top ten patent offices where Generation Bio is filings its patents..
University of Pennsylvania could be the strongest competitor for Generation Bio
Patents related to nanomedicine and rare diseases lead Generation Bio's portfolio
Generation Bio has the highest number of patents in nanomedicine followed by, rare diseases and cell & gene therapy. For nanomedicine, nearly 77% of patents were filed and no patents were granted in Q2 2024.
Progressive familial intrahepatic cholestasis related patents lead Generation Bio portfolio followed by hypoxia
Generation Bio has highest number of patents in progressive familial intrahepatic cholestasis followed by hypoxia.
For comprehensive analysis of Generation Bio's filings and grants, buy the databook here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.